Celularity Inc (CELU): Insider Trading, Congress Trades & Research | Tormere

CELU

$0.81-1.02%visit website

Celularity Inc

Market Cap

$26M

Live price × SEC shares (Oct 19, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.93

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

1.4

TTM to Jun 2026 · revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	5,284	4,104	3,846	5,432	18,666
Cost of revenue	3,904	7,374	1,452	2,347	15,077
Research & development	4,598	3,347	2,994	2,028	12,967
Selling, general & administrative	9,306	15,064	9,165	4,940	38,475
Operating income	(12,900)	(22,058)	(10,133)	(4,237)	(49,328)
Interest expense			352	177
Pretax income	(23,076)	(24,359)	874	706	(45,855)
Net income	(23,076)	(24,362)	874	706	(45,858)
EPS (basic) ($)	(0.88)		0.02	0.02	(1.69)
EPS (diluted) ($)	(0.88)		0.02	0.02	(1.69)
Weighted avg. shares (basic)	26,348		29,068	29,204
Weighted avg. shares (diluted)	26,348		30,300	29,345

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Oct 20, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 26 more quarters, back to Mar 2019, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Philip & Daniele Barach Family Trust · 2026-09-28

No Form 4 transactions on record.

Recent News

Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

Yahoo · 2026-10-29

One U.S. partner will finish making Vesalius’s peptide drug ingredients

Stock Titan · 2026-10-29

Celularity Enters Manufacturing Agreement With Vesalius For Its Peptual-Branded Peptide Active Pharmaceutical Ingredients

Benzinga · 2026-10-29

Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement

Yahoo · 2026-10-22

Celularity Regains Nasdaq Compliance

Benzinga · 2026-10-22

All three of Celularity’s Nasdaq compliance issues are now closed

Stock Titan · 2026-10-22

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Yahoo Finance · 2026-09-30

Celularity Announces Naveen Jain to Join Board of Directors

Yahoo Finance · 2026-09-29

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Investing News Network · 2026-09-24

Celularity shares jump 138.5% after forecasting $300 million MuseCell manufacturing revenue

TechStock² · 2026-08-28

Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity

Yahoo Finance · 2026-08-27

Why Celularity Stock Jumped 126% Today

Quiver Quantitative · 2026-08-27

Why Is Celularity Stock Gaining Thursday?

Benzinga · 2026-08-27

Celularity Provides Update Regarding Nasdaq Listing Compliance

Yahoo Finance · 2026-08-25

NexGel Files to Register 15.25 Million Shares From Note Conversions

Yahoo Finance · 2026-08-20

Informational purposes only, not investment advice.